24/7 Wall Street
17 Jan 2026, 10:36 UTC · 40w ago
Impact · against what's priced in
The news is negative for Apellis and Astellas as it confirms a structural patient access crisis in the geographic atrophy market that is actively stalling growth. While Apellis has a unique monopoly in rare disease via EMPAVELI, the slow commercial ramp fails to justify its current valuation multiples.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
SYFOVRE sales remained flat at $151 million in Q3 2025, with new patient share declining to 52%.
So whatStagnation in the company's primary revenue driver suggests a failure to scale and threatens the valuation based on aggressive growth.
More negative than 95% of claims this week
A structural patient access crisis and the cessation of co-pay assistance from the Good Days Foundation are hindering new patient enrollment for geographic atrophy treatments.
Continue reading
5 related stories
The company's shares surged following the acquisition of expanded commercial rights for a groundbreaking drug.
Read from the article alone
No priced-in read yet
Oppenheimer initiated coverage with an Outperform rating and a $10 price target.
Read from the article alone
No priced-in read yet
The stock price increased following the announcement of a key regulatory approval.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More negative than 92% of claims this week
EMPAVELI is the first and only approved treatment for C3G and IC-MPGN in the U.S., with potential for European expansion in December 2025.
So whatExclusive approval in a rare disease market provides significant pricing power and a long-term growth runway despite current slow execution.
More positive than 76% of claims this week
Apellis has reached 152 of its 225 guided cumulative patient start forms for EMPAVELI by September 2025.
More negative than 72% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Shares surged following the acquisition of expanded commercial rights for a groundbreaking drug.
More positive than 88% of ticker scores this week
Oppenheimer initiated coverage with an Outperform rating and a $10 price target.
More positive than 81% of ticker scores this week
Shares popped following the announcement of a key regulatory approval.
More negative than 84% of ticker scores this week
The company is facing commercial execution failures, stagnant sales for SYFOVRE, and a high valuation that the current launch trajectory doesn't support.
More negative than 78% of ticker scores this week
The company cut IZERVAY guidance by $200 million due to a patient access crisis in the geographic atrophy market.
More positive than 59% of ticker scores this week
Mentioned as a stock that remains afloat due to innovation and a favorable regulatory environment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
—
No price for ACCD right now — the quote feed didn't answer.
ACCD chart →—
No price for GWPH right now — the quote feed didn't answer.
GWPH chart →−56.8%
Price is moving against the score
$0.7307 vs $1.69 close before publication (Jan 16) · not market-adjusted
OCGN chart →
